Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioTime buys assets of Cell Targeting
The technology acquired from CTI uses peptides chosen for their capability to adhere to diseased tissue. By coating these peptides on the surfaces of therapeutic cells, CTI has
The technology acquired from CTI uses peptides chosen for their capability to adhere to diseased tissue. By coating these peptides on the surfaces of therapeutic cells, CTI has
Each party will hold 50% of the shares of the new company, and be equally represented on its management board. Bayer Zydus Pharma, which will operate in key
Out of $144,000 Bohai Pharma has received $91,000 (RMB 600,000) from the Ministry of Science and Technology of the People’s Republic of China and Yantai local government has
Additional contingent payments would be earned upon reaching various clinical efficacy and product approval milestones in both the US and European Union for up to six products. With
The primary endpoint of the study was the rate of complete remission with or without recovery of normal blood counts. In Accede trial, a regimen of AS1413 and
The transaction is expected to get closed by the end of February 2011. With is acquisition, Oxford BioMedica will have greater control of the production of its proprietary
Both the parties said that a research scientist at HUMC, Antoine Carlisle, will be the principal investigator for this research. Oxygen Biotherapeutics chief medical officer Gerald Klein said
The FDA approval was supported by the result from a pivotal Phase III trial data which evaluated the safety and immunogenicity of Menveo against each of the four
Earlier, Pfizer and Morphosys tied up in December 2003 to develop therapeutic antibodies. Both the parties further extended their collaboration in 2006 under which Pfizer secured an option
AMT holds the commercialization rights to the AIP gene therapy (AMT-021). Under this grant, AMT expects to obtain EUR1.1m, which will cover almost 75% of AMT’s overall development